Mallinson C N, Rake M O, Cocking J B, Fox C A, Cwynarski M T, Diffey B L, Jackson G A, Hanley J, Wass V J
Br Med J. 1980 Dec 13;281(6255):1589-91. doi: 10.1136/bmj.281.6255.1589.
Forty patients with inoperable pancreatic cancer were included in a prospective, randomised, controlled trial of multiple chemotherapy. The survival of 19 untreated control patients was compared with that of 21 patients who received an initiation course of intravenous fluorouracil, cyclophosphamide, methotrexate, and vincristine given over five days followed by intravenous fluorouracil and mitomycin given over three or five days at six-week intervals thereafter. Median survival in treated patients was 44 weeks, which was significantly longer than the nine weeks seen in controls. In patients without metastases median survival was 48 weeks in the treated group and 12 weeks in controls. In patients with metastases it was 30 weeks in treated patients and seven weeks in controls. The treatment was well tolerated and seemed to confer a significant prolongation of survival, comparing favourably with previous reports of chemotherapy with or without radiotherapy. If the results are confirmed this regimen may be useful in district general hospital practice.
40例无法手术的胰腺癌患者被纳入一项多药化疗的前瞻性随机对照试验。将19例未接受治疗的对照患者的生存率与21例接受初始疗程化疗的患者进行比较，初始疗程为静脉输注氟尿嘧啶、环磷酰胺、甲氨蝶呤和长春新碱，持续5天，随后静脉输注氟尿嘧啶和丝裂霉素，持续3或5天，此后每6周重复一次。治疗组患者的中位生存期为44周，显著长于对照组的9周。在无转移的患者中，治疗组的中位生存期为48周，对照组为12周。在有转移的患者中，治疗组为30周，对照组为7周。该治疗耐受性良好，似乎能显著延长生存期，与之前关于化疗联合或不联合放疗的报道相比更具优势。如果结果得到证实，该方案可能在地区综合医院的实践中有用。
